JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 27, 2005; DOI: 10.1124/jpet.105.090837

0022-3565/06/3162-940-945$20.00
JPET 316:940-945, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.090837v1
316/2/940    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Videla, S.
Right arrow Articles by Malagelada, J.-R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Videla, S.
Right arrow Articles by Malagelada, J.-R.

GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Selective Inhibition of Phosphodiesterase-4 Ameliorates Chronic Colitis and Prevents Intestinal Fibrosis

S. Videla, J. Vilaseca, C. Medina, M. Mourelle, F. Guarner, A. Salas, and J.-R. Malagelada

Digestive System Research Unit, Hospital Vall d'Hebron, Barcelona, Spain (S.V., J.V., C.M., M.M., F.G., J.-R.M.); and Department of Pathology, Hospital Mutua de Terrassa, Barcelona, Spain (A.S.)

The phosphodiesterase-4 (PDE4) inhibitors may be an important target in the treatment of several inflammatory conditions. The anti-inflammatory effect of PDE4 inhibitors bears similarities with that of steroids, without interfering with the hypophysary-adrenal-axis. We compared the effect of rolipram, a selective PDE4 inhibitor, with steroids on the clinical course of experimental colitis induced by 2,4,6-trinitrobenzenesulfonic acid (TNBS). Three groups of rats (n = 20) received TNBS. One group received methylprednisolone from day 7, another group received rolipram from the same day, and control group received no further treatment. On days 14 and 21 after TNBS instillation, sets of 10 rats underwent colonic dialysis to measure eicosanoid release. Colonic lesions were blindly scored, and colons were homogenized for quantification of myeloperoxidase (MPO) activity and collagen content. Concentration of tumor necrosis factor {alpha} (TNF-{alpha}) and transforming growth factor beta1 (TGF-beta1) in colonic tissue was also measured. Both treatments reduced significantly the eicosanoid release and MPO activity. On day 14, both rolipram and methylprednisolone significantly reduced TNF-{alpha} content, but TGF-beta1 was only inhibited by rolipram. On day 21, lesion scores and collagen content were significantly reduced only in rolipram-treated group. In conclusion, PDE4 inhibition by rolipram markedly ameliorates the course of chronic colitis and it is superior to methylprednisolone in preventing late collagen deposition.

Received June 10, 2005; accepted October 26, 2005.

Address correspondence to: Dr. Carlos Medina, Department of Integrative Biology and Pharmacology, Institute of Molecular Medicine for the Prevention of Human Diseases, University of Texas-Health Science Center at Houston, 6770 Bertner Ave., Delton A. Cooley Building, c950B, Houston, TX 77030. E-mail: cmedinammar{at}hotmail.com






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.